Cost-sharing provisions in commercial insurance plans and Medicare Part D options have led to much less-affordable specialty drugs in the market, according to an article published on Health Affairs.
The article’s authors aim to address how cost-sharing provisions and rising drug costs are threats to that affordability, and provide possible solutions to produce out-of-pocket costs protections for patients.
“Policies that include consideration of value for establishing cost sharing and coverage are more challenging to implement but may be a more promising long-term strategy,” the authors write.
According to the writeup, retail prescription drug spending reached almost $329 billion in 2016 on the heels of two years worth of “notable spending growth.”
Specialty drugs, the authors write, can be considered a main driver of the spending growth.